Literature DB >> 16470555

De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome.

Stefan Heinen1, Pilar Sanchez-Corral, Michael S Jackson, Lisa Strain, Judith A Goodship, Elizabeth J Kemp, Christine Skerka, T Sakari Jokiranta, Kevin Meyers, Eric Wagner, Pierre Robitaille, Jorge Esparza-Gordillo, Santiago Rodriguez de Cordoba, Peter F Zipfel, Timothy H J Goodship.   

Abstract

Many of the complement regulatory genes within the RCA cluster (1q32) have arisen through genomic duplication and the resulting high degree of sequence identity is likely to predispose to gene conversion events. The highest degree of identity is between the genes for factor H (CFH) and five factor H-related proteins--CFHL1, CFHL2, CFHL3, CFHL4, and CFHL5. CFH mutations are associated with atypical hemolytic uremic syndrome (aHUS). In the Newcastle cohort of 157 aHUS patients we have identified CFH mutations in 25 families or individuals. Eleven of these 25 independent mutations are either c.3226C>G,Q1076E; c.3572C>T,S1191L; c.3590T>C,V1197A or combined c.3572C>T,S1191L/c.3590T>C,V1197A. Sequence analysis shows that all four of these changes could have arisen as a result of gene conversion between CFH and CFHL1. Analysis of parental samples in two patients with S1191L/V1197A has shown that the changes are de novo thus providing conclusive evidence that gene conversion is the mutational mechanism in these two cases. To confirm that S1191L and V1197A are disease predisposing we examined their functional significance in three ways - analysis of the C3b/C3d binding characteristics of recombinant mutant S1191L/V1197A protein, heparin affinity chromatography and haemolytic assays of serum samples from aHUS patients carrying these changes. The results showed that these changes resulted in impaired C3b binding and a defective capacity to control complement activation on cellular surfaces. We, therefore, provide conclusive evidence that gene conversion is responsible for functionally significant CFH mutations in aHUS. 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16470555     DOI: 10.1002/humu.9408

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  47 in total

Review 1.  Complement control protein factor H: the good, the bad, and the inadequate.

Authors:  Viviana P Ferreira; Michael K Pangburn; Claudio Cortés
Journal:  Mol Immunol       Date:  2010-08       Impact factor: 4.407

2.  Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.

Authors:  Jessica Caprioli; Marina Noris; Simona Brioschi; Gaia Pianetti; Federica Castelletti; Paola Bettinaglio; Caterina Mele; Elena Bresin; Linda Cassis; Sara Gamba; Francesca Porrati; Sara Bucchioni; Giuseppe Monteferrante; Celia J Fang; M K Liszewski; David Kavanagh; John P Atkinson; Giuseppe Remuzzi
Journal:  Blood       Date:  2006-04-18       Impact factor: 22.113

Review 3.  CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.

Authors:  Peter F Zipfel; Thorsten Wiech; Emma D Stea; Christine Skerka
Journal:  J Am Soc Nephrol       Date:  2020-01-24       Impact factor: 10.121

Review 4.  Complementopathies.

Authors:  Andrea C Baines; Robert A Brodsky
Journal:  Blood Rev       Date:  2017-02-06       Impact factor: 8.250

5.  Frequent nonallelic gene conversion on the human lineage and its effect on the divergence of gene duplicates.

Authors:  Arbel Harpak; Xun Lan; Ziyue Gao; Jonathan K Pritchard
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-14       Impact factor: 11.205

Review 6.  Current treatment of atypical hemolytic uremic syndrome.

Authors:  Bernard S Kaplan; Rebecca L Ruebner; Joann M Spinale; Lawrence Copelovitch
Journal:  Intractable Rare Dis Res       Date:  2014-05

Review 7.  Genetics and complement in atypical HUS.

Authors:  David Kavanagh; Tim Goodship
Journal:  Pediatr Nephrol       Date:  2010-06-06       Impact factor: 3.714

Review 8.  Anti-complement-factor H-associated glomerulopathies.

Authors:  Marie-Agnes Dragon Durey; Aditi Sinha; Shambhuprasad Kotresh Togarsimalemath; Arvind Bagga
Journal:  Nat Rev Nephrol       Date:  2016-07-25       Impact factor: 28.314

Review 9.  The Genetics of Ultra-Rare Renal Disease.

Authors:  Melissa Muff-Luett; Carla M Nester
Journal:  J Pediatr Genet       Date:  2016-02-23

10.  Efficacy of plasma therapy in atypical hemolytic uremic syndrome with complement factor H mutations.

Authors:  Anne-Laure Lapeyraque; Eric Wagner; Véronique Phan; Marie-José Clermont; Aïcha Merouani; Véronique Frémeaux-Bacchi; Timothy H J Goodship; Pierre Robitaille
Journal:  Pediatr Nephrol       Date:  2008-04-19       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.